The pharmaceutical company has raised over $100m in equity funding from investors including Boehringer Ingelheim and Allergen.

US-based pharmaceutical company Vitae Pharmaceuticals filed for an initial public offering on Tuesday that could raise up to $55m.

Viate’s shareholders include pharmaceutical companies Boehringer Ingelheim International, which holds a 10.8% stake in the company, and Allergen, which owns 5.6%. The largest shareholders are venture capital firms Prospect Venture Partners (23.3%), New Enterprise Associates (17.8%), Venrock (15.6%) and Atlas Venture (11.2%).

Founded in 2001, Vitae is developing small molecule drugs for diseases including type diabetes and Alzheimer’s. The proceeds will…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?